Skip to main content
  • HighLife launches a new Large Annulus Valve in ongoing clinical studies for patients suffering from Mitral Regurgitation

    First patients successfully treated with the new Large Annulus Valve

    PARIS, September 06, 2023 – HighLife SAS, a medtech company focused on the development of a unique Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe mitral regurgitation (MR), announced today the introduction of a new valve size in its clinical trials, the Large Annulus Valve (LAV), designed for patients with larger anatomies.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details